Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H11NO.C3H6O3 |
| Molecular Weight | 227.257 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.CCC1=NC(C)=CC=C1O
InChI
InChIKey=LRUSSTVFELZALO-UHFFFAOYSA-N
InChI=1S/C8H11NO.C3H6O3/c1-3-7-8(10)5-4-6(2)9-7;1-2(4)3(5)6/h4-5,10H,3H2,1-2H3;2,4H,1H3,(H,5,6)
| Molecular Formula | C8H11NO |
| Molecular Weight | 137.179 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H6O3 |
| Molecular Weight | 90.0779 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.
Originator
Curator's Comment: In early 1980s, in State Institution Research Institute of Pharmacology of RAMS, by L.D. Smirnov and V.I. Kuzmin, 2-ethyl-6-methyl-3-hydroxypyridine succinate was synthesized, and under supervision of Academician of RAMS A.V. Valdman, its pharmacological effects were found, the mechanism of action was studied, preclinical studies on toxicology and pharmacokinetics were carried out, the Mexidol® trademark was identified, the drug was registered in the USSR Ministry of Healthcare, the first clinical trials and introduction of the preparation into medical practice were carried out.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model]. | 2001 Jan-Feb |
|
| [Antioxidant properties of 3-oxypyridine analogues: mexidol, emoxipin, proxipin]. | 2001 May-Jun |
|
| [Effect of emoxypine on myocardial electrical instability and homeostasis parameters in patients with acute disturbance of cerebrovascular circulation]. | 2002 May-Jun |
|
| [Effect of mexidol on the homeostasis and lipid peroxidation in paracetamol poisoning]. | 2002 Nov-Dec |
|
| The action of mexidol on the state of conditioned reflex activity after traumatic brain lesions. | 2003 Feb |
|
| GABAergic system in the anxiolytic effect of Proproten: experimental study. | 2003 Jan |
|
| [Mexidol-induced modification of lipid metabolism in pancreatitis]. | 2003 Jan-Feb |
|
| [Effects of complex therapy with emoxipin on the course of diabetic retinopathy]. | 2003 Mar-Apr |
|
| [A method for reproducing amnesia in mice by the complex extremal exposure]. | 2003 May-Jun |
|
| [Effect of low intensity laser light in the red range on macrophage superoxide dismutase activity]. | 2003 May-Jun |
|
| [Emoxipin in combined pharmacological defense of the kidney from ischemia and operative stress (an experimental study)]. | 2003 Sep-Oct |
|
| [Correction by 2-ethyl-6-methyl-3-hydroxypyridine succinate of the hepatotoxyc, caused at rats introduction tuberculostatics]. | 2004 |
|
| [Use of mexidol in stomatology: results and perspectives]. | 2004 |
|
| [Xerostomia. Diagnosis and treatment]. | 2004 |
|
| [Clinical and biochemical manifestations of chronic pyelonephritis and their correction in population of the northen areas of the Tyumen Territory]. | 2004 |
|
| [Efficacy of cytoprotective agent Mexicor in urgent cardiology]. | 2004 |
|
| [Effect of phenyl-tert-butylnitrone, mexidol and nooglutil on the ischemic lesion zone and memory in rats following middle cerebral artery occlusion]. | 2004 Jan-Feb |
|
| [The effect of mexidol on the process of glycolysis in rats under acute stress conditions]. | 2004 Jul-Aug |
|
| [The effects of Mexidol on food conditioning and synaptic fine structure of hippocampal field CA1 in rats exposed to a single acoustic stimulation with ultrasonic components]. | 2004 Mar-Apr |
|
| [Effect of hydroxymethylethylpyridine succinate on the cardiac electrophysiological and hemodynamic parameters during experimental thoracotomy and acute myocardial ischemia]. | 2004 May-Jun |
|
| [Effect of typical and atypical anxiolytics on the behavior and electrophysiological parameters of rats with model cerebrovascular pathology]. | 2004 Nov-Dec |
|
| [Investigation of the effects of mexidol in escapable and inescapable emotional stress in inbred BALB/C and C57BL/6 mice]. | 2004 Nov-Dec |
|
| [Pharmacological correction of memory impairment caused by a complex extremal action in mice with bilateral ligation of common carotid arteries]. | 2004 Sep-Oct |
|
| [The enzyme therapy within a complex treatment of hemophthalmos in patients with diabetes mellitus]. | 2004 Sep-Oct |
|
| [Study of antiradical activity of new compounds by chemiluminescence]. | 2005 May-Jun |
|
| [Neurometabolic therapy of diabetic neuropathy]. | 2006 |
|
| [The efficacy of oxynicotinic acid a nd its derivatives in respect of functional activity of hepatocytes during acute toxic hepatopathy]. | 2006 Oct-Dec |
|
| [The effectiveness of ascorbic acid and emoxipin in treatment of infiltrative pulmonary tuberculosis]. | 2007 |
|
| [The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents]. | 2007 |
|
| [Influence of gel Metrogil Denta and curative toothpaste Mexidol Dent activ on indices of parodontal status and lipid peroxidation in patients with chronic generalized catarrhal gingivitis]. | 2007 |
|
| [The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus]. | 2007 |
|
| Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation. | 2007 Apr |
|
| [Acute radiation sickness in experiment. Efficacy of mexidol]. | 2007 Jul-Sep |
|
| [Effect of mexidol on hemopoietic system in conditions of an emotional stress after exposure to ionizing radiation]. | 2007 Mar-Apr |
|
| [Combined action of mexidol and non-narcotic analgesics on pain thresholds and emotional stress behavior in animals]. | 2007 Mar-Apr |
|
| [Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology]. | 2007 Nov-Dec |
|
| [Experience with complex treatment for childhood amblyopia]. | 2008 Jan-Feb |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:10:21 GMT 2025
by
admin
on
Mon Mar 31 21:10:21 GMT 2025
|
| Record UNII |
84438Y4KT6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID601021786
Created by
admin on Mon Mar 31 21:10:21 GMT 2025 , Edited by admin on Mon Mar 31 21:10:21 GMT 2025
|
PRIMARY | |||
|
84438Y4KT6
Created by
admin on Mon Mar 31 21:10:21 GMT 2025 , Edited by admin on Mon Mar 31 21:10:21 GMT 2025
|
PRIMARY | |||
|
72941769
Created by
admin on Mon Mar 31 21:10:21 GMT 2025 , Edited by admin on Mon Mar 31 21:10:21 GMT 2025
|
PRIMARY | |||
|
220610-55-9
Created by
admin on Mon Mar 31 21:10:21 GMT 2025 , Edited by admin on Mon Mar 31 21:10:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |